Major Breakthrough in Blood Cancer Treatment: India Aims to Develop Affordable Gene Therapy by 2028

India is taking another step towards making advanced cancer treatments more accessible, with a new partnership focused on developing an innovative gene therapy for multiple myeloma, a serious form of blood cancer. The initiative aims to strengthen India's domestic capabilities in cell and gene therapy while potentially reducing the high cost associated with these advanced treatments.

The collaboration brings together Nucellion Therapeutics, a subsidiary of Bharat Biotech, and Hyderabad-based V-Gen Bio. The companies plan to work on a specialised CAR-T cell therapy, with the goal of beginning clinical trials in India and potentially launching the treatment commercially by 2028, subject to clinical results and regulatory approvals.

1. A New Partnership to Advance Cancer Treatment in India

The partnership is intended to strengthen India's ability to develop and manufacture advanced cancer therapies within the country.

Nucellion Therapeutics will serve as the manufacturing partner for V-Gen Bio's lead candidate, VL-2511. The collaboration is expected to involve technology transfer, manufacturing process development, and the production of therapy under appropriate quality standards.

Developing such treatments domestically could help build specialised manufacturing expertise, reduce reliance on overseas production, and improve the long-term availability of advanced therapies for eligible patients.

The initiative also reflects a broader effort to expand India's biotechnology sector and develop innovative medical treatments that may otherwise remain financially out of reach for many families.

2. What Is VL-2511 and How Does CAR-T Therapy Work?

VL-2511 is an investigational dual-target CAR-T cell therapy being developed for multiple myeloma, a cancer that affects plasma cells in the bone marrow.

CAR-T therapy is a form of personalised cancer treatment in which a patient's T cells, an important part of the immune system, are collected and genetically modified to recognise and attack cancer cells.

The modified cells are then multiplied and infused back into the patient.

VL-2511 is designed to target two proteins, BCMA and CD19, associated with certain cells involved in multiple myeloma. By targeting more than one marker, the treatment aims to help address a challenge known as antigen escape, in which cancer cells evade treatment by losing or reducing the target recognised by a therapy.

However, the effectiveness of this dual-target approach will need to be established through clinical studies.

It is not yet a proven cure, and its safety and benefits must be assessed in the patients for whom it is intended.

3. Why Could This Treatment Offer New Hope for Patients?

Multiple myeloma can be difficult to treat, particularly when the disease returns after earlier treatments or becomes resistant to available therapies.

CAR-T treatment offers a different approach by using a patient's own immune cells to recognise cancer. In some patients with difficult-to-treat blood cancers, CAR-T therapies have produced substantial responses, although outcomes vary according to the treatment and individual circumstances.

A dual-target treatment such as VL-2511 aims to reduce the likelihood that cancer cells will escape immune recognition. This could potentially be valuable for patients with limited treatment options.

Nevertheless, the reported experience with other CAR-T therapies cannot automatically be applied to VL-2511. Its actual response rates, durability of benefit, and safety profile will depend on the clinical evidence generated for this particular treatment.

4. Will Gene Therapy Become More Affordable in India?

Cost remains one of the biggest challenges associated with advanced cell and gene therapies. These treatments require specialised laboratories, carefully controlled manufacturing processes, highly trained medical teams, and close monitoring of patients.

Producing CAR-T cells in India could create opportunities to reduce manufacturing and supply-chain expenses. Establishing domestic production may also help develop the infrastructure needed to support future personalised cancer treatments.

Under the partnership, technology transfer and manufacturing process development are planned at a facility in Hyderabad. The companies intend to work towards appropriate manufacturing and quality standards, with the objective of making the treatment more accessible to Indian patients.

However, affordability will depend on the final treatment price, manufacturing costs, hospital charges, patient eligibility, and the availability of financial assistance.

A lower price has not yet been established simply by announcing the partnership.

5. When Could the Treatment Become Available?

The companies have outlined a target of initiating the first Phase 1/2 clinical trial in India and achieving a potential commercial launch by 2028.

Early-stage clinical trials are designed to evaluate safety, determine appropriate dosing, and gather preliminary evidence about whether a treatment works. Further studies and regulatory review may be required before a new therapy can be made widely available.

The proposed timeline is therefore a development target, not a guarantee that the treatment will be approved or available to every patient by 2028.

Progress will depend on clinical trial outcomes, manufacturing readiness, regulatory requirements, and the ability to demonstrate that the treatment's benefits outweigh its risks.

6. What Does This Mean for India's Healthcare Future?

The development of advanced therapies within India could have benefits beyond a single cancer treatment.

It may help strengthen domestic biotechnology research, create specialised manufacturing capabilities, and expand the country's experience with personalised medicine.

For patients, the long-term promise lies in the possibility of accessing innovative treatments closer to home and at a more manageable cost. For the healthcare sector, such partnerships could encourage further investment in research, clinical trials, and advanced treatment infrastructure.

At the same time, ensuring access will require trained specialists, suitable hospitals, reliable manufacturing, patient monitoring, and transparent pricing.

The Bottom Line

The partnership between Nucellion Therapeutics and V-Gen Bio represents a promising development in India's efforts to advance blood cancer treatment. Their proposed dual-target CAR-T therapy, VL-2511, is being developed for multiple myeloma, with a target of beginning clinical trials in India and potentially reaching the market by 2028.

Although the treatment could eventually expand options for patients with difficult-to-treat disease, its effectiveness, safety, affordability, and availability remain to be established. The coming stages of clinical development will determine whether this initiative can translate into a meaningful new treatment option for people living with blood cancer.